PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 138 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,025,503 | -25.3% | 61,481 | +23.8% | 0.00% | -25.0% |
| Q2 2023 | $1,372,079 | +64.9% | 49,677 | +37.3% | 0.00% | +100.0% |
| Q1 2023 | $831,887 | -32.0% | 36,169 | -67.8% | 0.00% | -50.0% |
| Q4 2022 | $1,224,047 | +241.9% | 112,195 | +163.9% | 0.00% | +300.0% |
| Q3 2022 | $358,000 | +2.0% | 42,513 | -4.1% | 0.00% | 0.0% |
| Q2 2022 | $351,000 | -72.3% | 44,333 | -17.1% | 0.00% | -66.7% |
| Q1 2022 | $1,267,000 | -42.6% | 53,500 | -17.2% | 0.00% | -25.0% |
| Q4 2021 | $2,209,000 | +75.0% | 64,600 | -9.3% | 0.00% | +33.3% |
| Q3 2021 | $1,262,000 | -54.4% | 71,200 | +15.6% | 0.00% | -50.0% |
| Q2 2021 | $2,765,000 | +98.8% | 61,600 | +14.7% | 0.01% | +100.0% |
| Q1 2021 | $1,391,000 | +24.5% | 53,700 | -3.1% | 0.00% | 0.0% |
| Q4 2020 | $1,117,000 | +8.0% | 55,400 | +4.7% | 0.00% | 0.0% |
| Q3 2020 | $1,034,000 | +542.2% | 52,900 | +132.0% | 0.00% | – |
| Q4 2019 | $161,000 | -41.2% | 22,800 | 0.0% | 0.00% | -100.0% |
| Q3 2019 | $274,000 | – | 22,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |